Eli Lilly and Company
Dr. Rotelli is currently the Senior Advisor for the Bioethics Program at Eli Lilly and Company in Indianapolois, Indiana. He leads the company’s evaluation of bioethical considerations across the continuum of its research, development, and commercialization activities. Dr. Rotelli has over 20 year of pharmaceutical development experience at Eli Lilly and Company. He has led multiple quantitative disciplines to bring medicines to patients in oncology, immunology, cardiovascular, endocrine, and neuroscience indications. He is passionate about making the drug development process more reliable, efficient, and trustworthy. Dr. Rotelli was formerly a Director of Pharmacokinetics, Pharmacodynamics (PK/PD), and Pharmacometrics and also a Director of Statistics. Previously, he was a Research Advisor in the Advanced Analytics Hub focusing on Data Mining and Bayesian applications. Throughout his career, he has performed or directed statistical and PK/PD work in all phases of clinical development, including commercialization, pharmacovigilance, and Health Outcomes.
Dr. Rotelli earned his B.A. in Mathematics from Cornell University and his M.S. and Ph.D. degrees in Statistics from Virginia Tech. He is a graduate of the Lilly Bioethics Leadership Academy (BELA) and a member of the American Statistical Association (ASA), the American Society for Bioethics and Humanites (ASBH), and Public Responsibility in Medicine and Research (PRIM&R). He is a former chair of the DIA Comparative Effectiveness Scientific Working Group and of the joint ASA and ISoP Statistics and Pharmacometrics Scientific Interest Group. Dr. Rotelli is currently on the Executive and Steering Committees of the MRCT Center and a member of the Biopharmaceutical Industry Bioethics Forum. He co-chairs the IFPMA Bioethics Working Group.